Percent of first milestone payment.

No definition available.

Name:	cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling
Namespace Prefix:	cvac_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percent of second milestone payment.

+ References

No definition available.

+ Details

Name:	cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans
Namespace Prefix:	cvac_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the closing date share price.

+ References

No definition available.

+ Details

Name:	cvac_PurchasePriceAllocationSharePriceAsOfClosingDate
Namespace Prefix:	cvac_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2021-01-01
-Paragraph B64
-Subparagraph f
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2021-01-01
-Paragraph B64
-Subparagraph m
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 3
-IssueDate 2021-01-01
-Paragraph B64
-Subparagraph i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2021-01-01
-Paragraph B64
-Subparagraph f
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_CashTransferred
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2021-01-01
-Paragraph B64
-Subparagraph f
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iii&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_LiabilitiesIncurred
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2021-01-01
-Paragraph B64
-Subparagraph f
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2021-01-01
-Paragraph 45
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2021-01-01
-Paragraph 45
-Subparagraph b
-Clause vi
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
Namespace Prefix:	ifrs-full_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	ifrs-full_ProductsAndServicesAxis=cvac_MilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent events (Details) € / shares in Units, € in Thousands		6 Months Ended
	Jul. 01, 2022 € / shares	Jun. 30, 2022 EUR (€) USD ($)	Jun. 08, 2022 EUR (€) USD ($) € / shares
Disclosure of detailed information about business combination [line items]
Shares transferred \| $		810,242
Net amount of discharging contractual obligations			€ 660
Closing date share price \| € / shares	€ 13.64
Percent of first milestone payment		50.00%
Cash acquired		€ 308
Transactions costs related to acquisition		€ 400
Average share price \| € / shares			€ 16.44
Milestones
Disclosure of detailed information about business combination [line items]
Percent of first milestone payment		50.00%
Minimum
Disclosure of detailed information about business combination [line items]
Cash payments		€ 250
Minimum \| Milestones
Disclosure of detailed information about business combination [line items]
Shares transferred \| $		194.647
Percent of second milestone payment		10.00%
Maximum
Disclosure of detailed information about business combination [line items]
Cash payments		€ 660
Maximum \| Milestones
Disclosure of detailed information about business combination [line items]
Shares transferred \| $		778.588
Percent of second milestone payment		40.00%
Frame Pharmaceuticals
Disclosure of detailed information about business combination [line items]
Total purchase price			€ 32,000
Shares transferred \| $			1,783,460